Delivery Order SPE2DB20D3103-SPE2DB25FP7L2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $1,288.86. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award utilized no set-aside designation and was...
- The Defense Logistics Agency awarded a $2,577.72 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 1 mg, a pharmaceutical product for immunosuppression. The contract, awarded on July 31, 2025, with completion targeted for August 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive procurement. Performance will occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) with a ceiling value of $1,553.40. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and has an ultimate completion date of August 18, 2025. The delivery order is being performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $1,711.95. This firm fixed price delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,288.86 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Envarsus XR 1 mg tablets (100-count package), with an ultimate completion date of August 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the federal government. The product will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count packaging). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle supporting military healthcare programs globally through December 2026....
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Envarsus XR 1 mg tablets (100-count packaging). This firm fixed price delivery order, valued at $2,148.10, is scheduled for completion by August 18, 2025, and represents a non-set-aside, competitively awarded contract. The delivery order is a child contract issued...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,718.48 for 100 tablets of Envarsus XR 1 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical delivery to support federal medical procurement needs. The contract does not include a set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,711.95 on August 11, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages). This is a firm fixed-price, non-set-aside contract with a completion date of September 2, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was competitively selected to fulfill...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,361.58 for Envarsus XR 1 mg tablets (30-count supply) on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Envarsus XR is an extended-release immunosuppressant medication used primarily in...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP7L2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,035.60 on August 5, 2025, with an ultimate completion date of August 26, 2025. The contract involves the supply of Envarsus XR 1 mg tablets in a 30-tablet quantity under firm fixed-price terms. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction typical of routine pharmaceutical replenishment within the DLA Medical Supply Chain. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies supporting military healthcare operations globally. Envarsus XR, an immunosuppressant medication, falls within the specialized pharmaceutical portfolio that AmerisourceBergen regularly delivers to federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard, demonstrating the contractor's capacity to fulfill critical medication requirements across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/5/25 |